Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity

Blood

Volumn 126, Issue 1, 2015, Pages 94-102

  Ivanciu, Lacramioara ^a   Camire, Rodney M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; HEMOSTATIC AGENT; PROTHROMBIN; UNCLASSIFIED DRUG; ZYMOGEN LIKE FACTOR XA; ENZYME PRECURSOR; MUTANT PROTEIN; THROMBOPLASTIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BLEEDING; BLOOD CLOTTING TIME; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC ENGINEERING; GENETIC VARIABILITY; HEMOPHILIA; HUMAN; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BLOOD CLOTTING; CHEMISTRY; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; ENZYME ACTIVE SITE; GENETICS; HALF LIFE TIME; HEMOPHILIA A; ISOLATION AND PURIFICATION; METABOLISM; SYNTHESIS;

ANIMALS; BLOOD COAGULATION; CATALYTIC DOMAIN; DNA MUTATIONAL ANALYSIS; ENZYME PRECURSORS; FACTOR XA; HALF-LIFE; HEMOPHILIA A; HEMOSTATICS; MICE; MICE, INBRED BALB C; MUTANT PROTEINS; PROTHROMBIN; THROMBOPLASTIN;

EID: 84937780393     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-634329     Document Type: Article

References (35)

1. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet. 2012;379(9824):1447-1456.
2. Pipe SW. Hemophilia: new protein therapeutics. Hematology Am Soc Hematol Educ Program. 2010;2010:203-209.
3. Kaufman RJ, Powell JS. Molecular approaches for improved clotting factors for hemophilia. Blood. 2013;122(22):3568-3574.
4. Schaub RG. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. Biochem Pharmacol. 2011;82(2):91-98.
5. Toso R, Zhu H, Camire RM. The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly. J Biol Chem. 2008; 283(27):18627-18635.
6. Bunce MW, Toso R, Camire RM. Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro. Blood. 2011;117(1):290-298.
7. Ivanciu L, Toso R, Margaritis P, et al. A zymogenlike factor Xa variant corrects the coagulation defect in hemophilia. Nat Biotechnol. 2011;29(11): 1028-1033.
8. Huber R, Bode W. Structural basis of the activation and action of trypsin. Acc Chem Res. 1978;11(3):114-122.
9. Khan AR, James MN. Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci. 1998;7(4):815-836.
10. Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J. The refined 1.9 A crystal structure of human a-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 1989;8(11):3467-3475.
11. Bode W, Schwager P, Huber R. The transition of bovine trypsinogen to a trypsin-like state upon strong ligand binding. The refined crystal structures of the bovine trypsinogen-pancreatic trypsin inhibitor complex and of its ternary complex with Ile-Val at 1.9 A resolution. J Mol Biol. 1978;118(1):99-112.
12. Bode W. The transition of bovine trypsinogen to a trypsin-like state upon strong ligand binding. II. The binding of the pancreatic trypsin inhibitor and of isoleucine-valine and of sequentially related peptides to trypsinogen and to p-guanidinobenzoate-trypsinogen. J Mol Biol. 1979;127(4):357-374.
13. Lottenberg R, Jackson CM. Solution composition dependent variation in extinction coefficients for p-nitroaniline. Biochim Biophys Acta. 1983; 742(3):558-564.
14. Higgins DL, Lewis SD, Shafer JA. Steady state kinetic parameters for the thrombin-catalyzed conversion of human fibrinogen to fibrin. J Biol Chem. 1983;258(15):9276-9282.
15. Camire RM. Prothrombinase assembly and S1 site occupation restore the catalytic activity of FXa impaired by mutation at the sodium-binding site. J Biol Chem. 2002;277(40):37863-37870.
16. Toso R, Camire RM. Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized. J Biol Chem. 2004; 279(20):21643-21650.
17. Buddai SK, Toulokhonova L, Bergum PW, Vlasuk GP, Krishnaswamy S. Nematode anticoagulant protein c2 reveals a site on factor Xa that is important for macromolecular substrate binding to human prothrombinase. J Biol Chem. 2002; 277(29):26689-26698.
18. Kisiel W, Hermodson MA, Davie EW. Factor X activating enzyme from Russell's viper venom: isolation and characterization. Biochemistry. 1976;15(22):4901-4906.
19. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33(1):4-15.
20. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood. 1997;90(10):3962-3966.
21. Kung SH, Hagstrom JN, Cass D, et al. Human factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood. 1998;91(3):784-790.
22. Schlachterman A, Schuettrumpf J, Liu JH, et al. Factor V Leiden improves in vivo hemostasis in murine hemophilia models. J Thromb Haemost. 2005;3(12):2730-2737.
23. Straume M, Johnson ML. Analysis of residuals: criteria for determining goodness-of-fit. Methods Enzymol. 1992;210:87-105.
24. Segal IH. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady State Enzyme Systems. New York: John Wiley & Sons, Inc.; 1975.
25. Rezaie AR. Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by a template mechanism. Evidence that calcium alleviates Gla domain antagonism of heparin binding to factor Xa. J Biol Chem. 1998;273(27): 16824-16827.
26. Rezaie AR. Identification of basic residues in the heparin-binding exosite of factor Xa critical for heparin and factor Va binding. J Biol Chem. 2000; 275(5):3320-3327.
27. Rudolph AE, Porche-Sorbet R, Miletich JP. Definition of a factor Va binding site in factor Xa. J Biol Chem. 2001;276(7):5123-5128.
28. Levigne S, Thiec F, Cherel G, Irving JA, Fribourg C, Christophe OD. Role of the alpha-helix 163-170 in factor Xa catalytic activity. J Biol Chem. 2007;282(43):31569-31579.
29. Björk I, Olson ST. Antithrombin. A bloody important serpin. Adv Exp Med Biol. 1997;425: 17-33.
30. Persson E, Bolt G, Steenstrup TD, Ezban M. Recombinant coagulation factor VIIa-from molecular to clinical aspects of a versatile haemostatic agent. Thromb Res. 2010;125(6): 483-489.
31. Negrier C, Dargaud Y, Bordet JC. Basic aspects of bypassing agents. Haemophilia. 2006; 12(Suppl 6):48-52.
32. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol. 2002;22(9):1381-1389.
33. Giles AR, Nesheim ME, Mann KG. Studies of Factors V and VIII:C in an animal model of disseminated intravascular coagulation. J Clin Invest. 1984;74(6):2219-2225.
34. Giles AR, Mann KG, Nesheim ME. A combination of factor Xa and phosphatidylcholinephosphatidylserine vesicles bypasses factor VIII in vivo. Br J Haematol. 1988;69(4):491-497.
35. TM;2 investigators. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost. 2014; 12(8):1244-1253.